4//SEC Filing
FRATTAROLI JOSEPH 4
Accession 0001104659-20-140307
CIK 0001750149other
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 9:52 PM ET
Size
9.2 KB
Accession
0001104659-20-140307
Insider Transaction Report
Form 4
FRATTAROLI JOSEPH
Chief Financial Officer
Transactions
- Conversion
Common Stock
2020-12-28$10.00/sh+44,143$441,430→ 44,143 total(indirect: By Flagship Consulting, Inc.) - Award
Stock Option (right to buy)
2020-12-22+100,000→ 100,000 totalExercise: $10.00Exp: 2030-12-22→ Common Stock (100,000 underlying) - Conversion
Convertible Note
2020-12-28→ 0 total(indirect: By Flagship Consulting, Inc.)Exercise: $10.00From: 2020-12-28Exp: 2021-12-31→ Common Stock (44,143 underlying)
Footnotes (1)
- [F1]One-third of the option will vest and become exercisable on 12/22/2021, and the remaining portion will vest and become exercisable in 24 equal monthly installments commencing on the first day of the month beginning January 1, 2022.
Documents
Issuer
Inhibikase Therapeutics, Inc.
CIK 0001750149
Entity typeother
Related Parties
1- filerCIK 0001272668
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 9:52 PM ET
- Size
- 9.2 KB